C-Major Medical, a medical device product development company based at Sci-Tech Daresbury, using its innovative technology platform to radically reduce the number of needle stick injuries (NSI’s) globally, has secured additional equity investment. The funding will be used in conjunction with a grant made to the company by Innovate UK to complete the design of the first two novel safety syringe devices for blood collection using its novel syringe platform technology – CHoRDä.
This round was led by the UK Innovation and Science Seed Fund (UKI2S), and supported by equity investments from the founders of the company, existing shareholders and new investors under the EIS Scheme.
Commenting on the first round closing, Chairman Simon Douglas said “The award of this grant and further investment from our shareholders marks a significant step in the development of the company as we complete the design of our first products and move ever closer to making the clinic a safer place to work in.”
Aubrey Dunford, CEO, added “UKI2S have proved to be a very valuable partner for us, as they have supported us in many ways including mentorship and strategic planning, as well as leading this investment round.”
C-Major’s first two products will be Auto-Retractable Syringes capable of providing safety during both blood collection and injection. Both of these products use the Company’s CHoRDä technology containing a patented ‘helical track’ mechanism for controlled acceleration of the needle during retraction. These CHoRDä-based products have unique features to prevent NSIs and reduce blood aerosols not seen in other safety devices.
In the near term the company will be raising additional finance to complete the design for manufacture and assembly (DFMA) phase, at which point the device will be ready to move forward into manufacturing and regulatory submission.